Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

SNS Insider Reveals Sharp Growth in U.S. Retinal Biologics Market, Valued at USD 9.70 Billion in 2023 Capturing Over 43% Global Share Amid FDA Approvals, VEGF-A Dominance, and Accelerating R&D in ...

In this video from Clinical Trials at the Summit, Carl D. Regillo, MD, FACS, discusses the use of tyrosine kinase inhibitors for wet age-related macular degeneration and diabetic retinopathy with ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

Sean Clark, the VP and general manager of Alcon’s Global Surgical Franchise, added: “Dry AMD is an area of significant unmet ...

Global ophthalmologists and industry experts have called for innovation and advancement of global ophthalmic technology, as ...

Blurry, distorted vision is a common symptom of wet AMD (age-related macular degeneration). Your eyes may also have difficulty adjusting to changes in lighting.